With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ALK-positive lung cancer trial results show unprecedented progression-free survival.

2.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

3.

Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer

4.

Children with cancer tumors lacking DNA repair may benefit from olaparib combined with ceralasertib.

5.

Resection for Early Liver Cancer Tied to Improved Survival.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot